The Lynx Group

ESMO

New results from the PATHFINDER clinical trial suggest that a multicancer early detection blood test can accurately identify the presence of cancer in apparently healthy people. The test, known as Galleri (developed by GRAIL), uses cell-free DNA and machine learning to detect a common cancer signal across more than 50 cancer types as well as to predict cancer signal origin. Once the test is validated and refined further, it may revolutionize the way in which cancer is diagnosed and treated.
Read Article

In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals.
Read Article

Although the combination of 2 antivascular agents showed preliminary efficacy, increased cardiac toxicity has resulted in premature discontinuation of the trial.
Read Article

The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity.
Read Article

Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.
Read Article

Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo.
Read Article

Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer.
Read Article

Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation.
Read Article

Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens.
Read Article

Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated, BRCA-wildtype ovarian cancer patients.
Read Article

Page 1 of 8


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: